|Tested species reactivity||Human, Mouse, Rat|
|Published species reactivity||Yeast, Rat, Human, Mouse|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant rat c-erbB-3/HER-3 oncoprotein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||3-5 µg/10^6 cells|
|Immunoprecipitation (IP)||2 µg/ml|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13053 targets HER-3 in IP and WB applications and shows reactivity with Human, mouse, and Rat samples.
The MA5-13053 immunogen is recombinant rat c-erbB-3/HER-3 oncoprotein.
c-erbB-3/HER-3 is the third member of the type I family of growth factor receptors. It binds to ligands in the heregulin family. c-erbB-3 is over-expressed in a variety of tumors including breast, stomach, pancreas, and colon. Heregulin and EGF stimulate tyrosine phosphorylation of c-erbB-3 to different extents.
IP-MS enrichment of ERBB3 (LFQ intensity): ERBB3 was enriched 165-fold from MCF7 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB3 antibody (Part No. MA5-13053). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells.
MA5-13053 was used in western blot to study the downregulation of erbB2, erbB3 and apoptosis in breast cancer cells treated with and HDAC1 inhibitor and the roles played by miRNA-125a, miRNA125b and miRNA-205
|Wang S,Huang J,Lyu H,Lee CK,Tan J,Wang J,Liu B||Cell death and disease (4:null)||2013|
Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
MA5-13053 was used in western blot to study the role of estrogen receptor and erb2/erb3 signaling in estrogen-induced mitogenesis in mammary cancer cells
|Liu B,Ordonez-Ercan D,Fan Z,Huang X,Edgerton SM,Yang X,Thor AD||Molecular cancer research : MCR (7:1882)||2009|
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
MA5-13053 was used in western blot to investigate the mechanism of acute resistance to TRAIL treatment
|Van Schaeybroeck S,Kelly DM,Kyula J,Stokesberry S,Fennell DA,Johnston PG,Longley DB||Cancer research (68:8312)||2008|
Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.
MA5-13053 was used in western blot to examine the mechanism for opposite EGF responses among different species
|Kiley SC,Chevalier RL||American journal of physiology. Renal physiology (293:F895)||2007|
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
MA5-13053 was used in western blot to study the role of erbB3 in erbB2-mediated tamoxifen resistance in breast cancer cells
|Liu B,Ordonez-Ercan D,Fan Z,Edgerton SM,Yang X,Thor AD||International journal of cancer (120:1874)||2007|
H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent.
MA5-13053 was used in western blot to investigate the mechanism for radioresistance induced by H-RAS V12 in HCT116 cells
|Carón RW,Yacoub A,Zhu X,Mitchell C,Han SI,Sasazuki T,Shirasawa S,Hagan MP,Grant S,Dent P||Molecular cancer therapeutics (4:243)||2005|
A new superinvasive in vitro phenotype induced by selection of human breast carcinoma cells with the chemotherapeutic drugs paclitaxel and doxorubicin.
MA5-13053 was used in western blot to use paclitaxel and doxorubicin to select human breast carcinoma cells with a superinvasive phenotype
|Glynn SA,Gammell P,Heenan M,O'Connor R,Liang Y,Keenan J,Clynes M||British journal of cancer (91:1800)||2004|
ErbB2 and EGFR are downmodulated during the differentiation of 3T3-L1 preadipocytes.
MA5-13053 was used in western blot to study the downregulation of ErbB2 and EGFR during 3T3-L1 preadipocyte differentiation
|Pagano E,Calvo JC||Journal of cellular biochemistry (90:561)||2003|
Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor.
MA5-13053 was used in western blot to study the role of a dominant-negative EGFR in the radiosensitization of malignant glioma cells
|Lammering G,Valerie K,Lin PS,Mikkelsen RB,Contessa JN,Feden JP,Farnsworth J,Dent P,Schmidt-Ullrich RK||Clinical cancer research : an official journal of the American Association for Cancer Research (7:682)||2001|
ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.
MA5-13053 was used in western blot to study the interaction between ErbB3 and the SH2 domains of the p85 regulatory subunit of phosphoinositide 3-kinase.
|Hellyer NJ,Cheng K,Koland JG||The Biochemical journal (333 ( Pt 3):757)||1998|
A physical mechanism for coupling bone resorption and formation in adult human bone.
MA5-13053 was used in immunohistochemistry to investigate the molecular mechanism of bone remodeling with osteoclasts and osteoblasts
|Andersen TL,Sondergaard TE,Skorzynska KE,Dagnaes-Hansen F,Plesner TL,Hauge EM,Plesner T,Delaisse JM||The American journal of pathology (174:239)||2009|